Cheng Hao, Yang Jun, Fu Xu, Mao Liang, Chu Xuehui, Lu Chenglin, Li Gang, Qiu Yudong, He Wei
Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Front Oncol. 2022 Oct 13;12:1012609. doi: 10.3389/fonc.2022.1012609. eCollection 2022.
To evaluate the prognostic impact of folate receptor (FR)-positive circulating tumor cells (FR CTCs) for patients with pancreatic cancer (PC).
Risk stratification before surgery for PC patients remains challenging as there are no reliable prognostic markers currently. FR CTCs, detected by ligand-targeted polymerase chain reaction (LT-PCR), have shown excellent diagnostic value for PC in our previous study and prognostic value in a variety of cancer types.
Peripheral blood samples from 44 consecutive patients diagnosed with PC were analyzed for FR CTCs. 25 patients underwent tumor resection and were assigned to the surgical group. 19 patients failed to undergo radical resection because of local advance or distant metastasis and were assigned to the non-surgical group. The impact of CTCs on relapse and survival were explored.
For the prognostic stratification, the optimal cut-off value of CTCs analyzed by receiver operating characteristic (ROC) curve was 14.49 folate units (FU)/3 ml. High CTC levels (> 14.49 FU/3 ml) were detected in 52.0% (13/25) of the patients in the surgical group and 63.2% (12/19) in the non-surgical group. In the surgical group, median disease-free survival (DFS) for patients with high CTC levels versus low CTC levels (< 14.49 FU/3 ml) was 8.0 versus 26.0 months ( = 0.008). In multivariable analysis, CTCs were an independent risk factor for DFS (HR: 4.589, = 0.012). Concerning the recurrence patterns, patients with high CTC levels showed a significantly frequent rate of distant and early recurrence ( = 0.017 and = 0.011). CTC levels remained an independent predictor for both distant (OR: 8.375, = 0.014) and early recurrence (OR: 8.412, = 0.013) confirmed by multivariable logistic regression. However, CTCs did not predict survival in the non-surgical group ( = 0.220).
FR CTCs in resected PC patients could predict impaired survival and recurrence patterns after surgery. Preoperative CTC levels detected by LT-PCR may help guide treatment strategies and further studies in a larger cohort are warranted.
评估叶酸受体(FR)阳性循环肿瘤细胞(FR CTCs)对胰腺癌(PC)患者的预后影响。
由于目前尚无可靠的预后标志物,PC患者术前的风险分层仍然具有挑战性。在我们之前的研究中,通过配体靶向聚合酶链反应(LT-PCR)检测到的FR CTCs对PC显示出优异的诊断价值,并且在多种癌症类型中具有预后价值。
对44例连续诊断为PC的患者的外周血样本进行FR CTCs分析。25例患者接受了肿瘤切除并被分配到手术组。19例患者因局部进展或远处转移未能接受根治性切除,被分配到非手术组。探讨了CTCs对复发和生存的影响。
对于预后分层,通过受试者工作特征(ROC)曲线分析的CTCs的最佳截断值为14.49叶酸单位(FU)/3 ml。手术组中52.0%(13/25)的患者和非手术组中63.2%(12/19)的患者检测到高CTCs水平(>14.49 FU/3 ml)。在手术组中,高CTCs水平患者与低CTCs水平患者(<14.49 FU/3 ml)的无病生存期(DFS)中位数分别为8.0个月和26.0个月(P = 0.008)。在多变量分析中,CTCs是DFS的独立危险因素(HR:4.589,P = 0.012)。关于复发模式,高CTCs水平的患者远处复发和早期复发率显著更高(P = 0.017和P = 0.011)。多变量逻辑回归证实,CTCs水平仍然是远处复发(OR:8.375,P = 0.014)和早期复发(OR:8.412,P = 0.013)的独立预测因素。然而,CTCs在非手术组中不能预测生存(P = 0.220)。
接受手术的PC患者中的FR CTCs可以预测术后生存受损和复发模式。通过LT-PCR检测的术前CTCs水平可能有助于指导治疗策略,并且有必要在更大的队列中进行进一步研究。